EyeGene, Inc. is a company located in Seoul, South Korea. It was established in June 2000 as Igene Co., Ltd. and focuses on bio-drug development to address the challenges of aging and improve the quality of life. The company is engaged in ongoing research and development of biopharmaceuticals. EyeGene's core technologies are divided into two main categories. The first is proteomics-based technology, which is utilized in the development of a drug candidate called EGT022. This drug is being developed for the treatment of diabetic retinopathy, pressure ulcers, wounds, myocardial ischemia, and reperfusion injury. The second category is immunology, where EyeGene is actively developing a range of premium vaccines for adults using their unique adjuvant established through research. The company aims to become a leader in the field of life sciences in the 21st century by developing various new drugs, preventive vaccines, and diagnostics for the treatment and prevention of geriatric diseases. Their ultimate goal is to enhance the quality of human life.
Headquarters
330 Seongam-Ro, Mapo-Gu
Seoul; Seoul;
Contact Details: Purchase the EyeGene, Inc. report to view the information.
Website: http://www.eyegene.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service